Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Boccardo F, Amadori D, Guglielmini P, Sismondi P, Farris A, Agostara B, Gambi A, Catalano G, Faedi M, Rubagotti A. Boccardo F, et al. Among authors: farris a. Oncology. 2010;78(3-4):274-81. doi: 10.1159/000315735. Epub 2010 Jun 8. Oncology. 2010. PMID: 20530973 Clinical Trial.
Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study.
Gebbia V, Mantovani G, Farris A, Agostara B, Desogus A, Curreli L, Moschella F, Di Gregorio C, Bajetta E, Gebbia N. Gebbia V, et al. Among authors: farris a. Cancer. 1997 Apr 1;79(7):1394-400. doi: 10.1002/(sici)1097-0142(19970401)79:7<1394::aid-cncr17>3.0.co;2-v. Cancer. 1997. PMID: 9083162 Clinical Trial.
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L; Epirubicin-Lonidamine Group, Orbassano, Torino, Italy. Berruti A, et al. Among authors: farris a. J Clin Oncol. 2002 Oct 15;20(20):4150-9. doi: 10.1200/JCO.2002.08.012. J Clin Oncol. 2002. PMID: 12377958 Clinical Trial.
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial.
Mustacchi G, Ceccherini R, Milani S, Pluchinotta A, De Matteis A, Maiorino L, Farris A, Scanni A, Sasso F; Italian Cooperative Group GRETA. Mustacchi G, et al. Among authors: farris a. Ann Oncol. 2003 Mar;14(3):414-20. doi: 10.1093/annonc/mdg117. Ann Oncol. 2003. PMID: 12598347 Free article. Clinical Trial.
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
Gebbia V, Mantovani G, Agostara B, Contu A, Farris A, Colucci G, Cognetti F, Restivo G, Speciale R, Ferrero B, et al. Gebbia V, et al. Among authors: farris a. Ann Oncol. 1995 Dec;6(10):987-91. doi: 10.1093/oxfordjournals.annonc.a059095. Ann Oncol. 1995. PMID: 8750150 Free article. Clinical Trial.
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
Tampellini M, Berruti A, Bitossi R, Gorzegno G, Alabiso I, Bottini A, Farris A, Donadio M, Sarobba MG, Manzin E, Durando A, Defabiani E, De Matteis A, Ardine M, Castiglione F, Danese S, Bertone E, Alabiso O, Massobrio M, Dogliotti L. Tampellini M, et al. Among authors: farris a. Breast Cancer Res Treat. 2006 Aug;98(3):241-8. doi: 10.1007/s10549-005-9155-y. Epub 2006 May 3. Breast Cancer Res Treat. 2006. PMID: 16670941
Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA).
Boccardo F, Rubagotti A, Amoroso D, Perrotta A, Sismondi P, Farris A, Mesiti M, Gallo L, Pacini P, Villa E, Agostara B. Boccardo F, et al. Among authors: farris a. Cancer Invest. 1997;15(6):505-12. doi: 10.3109/07357909709047591. Cancer Invest. 1997. PMID: 9412655 Clinical Trial.
Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer.
Martoni A, Guaraldi M, Piana E, Strocchi E, Petralia A, Busutti L, Preti P, Robustelli G, Raimondi M, Ferrara G, Palomba G, Lelli G, Picece V, Recaldin E, Caffo O, Ambrosini G, Sarobba G, Farris A, Pannuti F. Martoni A, et al. Among authors: farris a. Lung Cancer. 1998 Oct;22(1):31-8. doi: 10.1016/s0169-5002(98)00065-8. Lung Cancer. 1998. PMID: 9869105 Clinical Trial.
464 results